The treatment of multiple sclerosis has made enormous progress thanks to highly effective disease-modifying therapies, in particular anti-CD20 antibodies. For most newly diagnosed patients, a life without disability is realistic. However, the focus is now shifting from preventing acute relapses to combating the insidious progression of disability. New approaches target cellular mechanisms in the CNS and the promotion of remyelination.
Autoren
- Dr. Ulf Blanke
Publikation
- InFo NEUROLOGIE & PSYCHIATRIE
You May Also Like
- MASLD/MASH
Drug therapy options on the rise: spectacular evidence
- New ways of neuroregeneration
CRISPR and artificial intelligence
- Asbestos victims
Federal Council has decided to amend the UVG
- Music as a cure for cancer?
Music therapy in Swiss oncology
- Clinical significance, pathophysiology, diagnosis and management
Frailty in COPD
- Bladder infections and urinary tract infections
Survey reveals information deficits in the population
- Early detection of type 1 diabetes
Detection of insulin autoantibodies as an early marker
- Type 2 diabetes